Becton Dickinson is currently attractive primarily to defensive value and dividend investors who are looking for a crisis-proof “dividend king” with a solid yield and upside potential following several years of undervaluation. Pure growth investors, on the other hand, will find little momentum, as revenue growth is anchored in the mid-single-digit percentage range. For long-term investors, the price level around $180 offers an attractive risk-reward ratio for a defensive core investment.
Breakout/Recovery: The recent momentum is driven by improved quarterly results, an upward revision to the full-year 2026 earnings forecast, progress in debt reduction, and positive study results in the core vascular segment (AGILITY study).
Dividend
Dividend Payer & Status: Yes. Becton Dickinson belongs to the elite group of “Dividend Kings” and has increased its dividend for 54 consecutive years.
Current dividend yield: approx. 2.33% (current quarterly dividend of $1.05 per share, or $4.20 annualized).
Dividend growth (last 5 years): Dividend growth over the past five years averaged a solid 5.0% to 5.2% per year (CAGR). This represents steady, defensive growth that keeps pace with inflation.
Security & Payout Ratio:
Adjusted Payout Ratio: Based on adjusted earnings (non-GAAP EPS), the ratio is a moderate approximately 32% to 33%.
Free Cash Flow Coverage: Based on free cash flow, the payout ratio is less than 30%.
Thanks to its crisis-resistant business model with recurring revenue from medical consumables (syringes, infusion systems, diagnostics), the dividend is considered exceptionally secure.
Historical Comparison: On a 5- to 10-year average, Becton Dickinson has typically traded at a forward P/E ratio between 18 and 22. On an adjusted basis, the stock is therefore currently historically undervalued.
Future success will depend on how seamlessly the APM hemodynamic sensors are integrated into the Alaris and Incada platforms and to what extent the BD Excellence efficiency program can protect operating margins against ongoing increases in labor and material costs. If this symbiosis of software and devices is successfully and consistently implemented, New BD will remain one of the most resilient and profitable players in the global medical technology market.
